Georgia News Desk

Hemophilia Market Size is Predicted to Attain $16.9 Billion by 2026: Grand View Research, Inc

 Breaking News
  • No posts were found

Hemophilia Market Size is Predicted to Attain $16.9 Billion by 2026: Grand View Research, Inc

June 07
04:39 2019
Hemophilia Market Size is Predicted to Attain $16.9 Billion by 2026: Grand View Research, Inc

Grand View Research, Inc. – Market Research And Consulting.
According to report published by Grand View Research, The Presence of limited therapies and rising burden over the regulatory authorities toward treatment of these disorders is expected to drive R&D focused on identifying curative agents. This, in turn, is expected to boost hemophilia market growth during the forecast period.

According to a report, Hemophilia Market Analysis by Type (Hemophilia A, Hemophilia B, Hemophilia C), by Treatment (On-demand, Prophylaxis), by Therapy (Replacement Therapy, Gene Therapy), And Segment Forecasts, 2019 – 2026, published by Grand View Research, Inc., The global Hemophilia Market is expected to reach USD 16.9 billion by 2026, according to a new report by Grand View Research, Inc. Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver.

Key Takeaways from the report:

  • Hemophilia B is expected to be the fastest growing hemophilia type over the forecast period, at a CAGR of 5.8%.
  • The other segment, owing to spurt in the number of patients diagnosed with von Willebrand Disease (VWD), is also anticipated to witness lucrative growth over the forecast period.
  • On-demand treatment dominated the segment over the forecast period and is expected to contribute more than 50.0% by 2026.
  • On the basis of therapy, gene therapy is expected to be the fastest growing segment as a result of increasing R&D and innovations in the field. Furthermore, replacement therapy is expected to witness lucrative growth due to the launch of extended half-life versions of currently available drugs.
  • Major market players include Biogen, Novo Nordisk, Baxalta, Octapharma, CSL Behring, Pfizer, Inc., and Bayer Healthcare. Most of the companies are actively involved in the awareness and treatment programs launched by regional governments and hemophilia associations.

U.S. Hemophilia market size, by type, 2015 - 2026 (USD Billion)

Browse More Reports in Medical Devices Industry:

Atrial Fibrillation Market: The most important factor driving atrial fibrillation market is the global aging population combined with the changes in lifestyle increasing the risks of obesity and high blood pressure. 

Antidiabetics Market: The global antidiabetics market was valued at USD 41,609.7 million in 2013. Growing worldwide prevalence of diabetes (both type I and type II) is expected to be a key driver. 

CDC’s National Center on Birth Defects and Developmental Disabilities (NCBDDD) undertakes initiatives to improving the public understanding of blood disorders and associated complications. For instance, NCBDDD supported the ‘The Red Tie Challenge’ initiated by the National Hemophilia Foundation (NHF) in order to spread awareness about blessing disorders such as Von Willebrand disease, hemophilia and other rare bleeding disorders. Such initiatives are anticipated to boost the market growth

The market players are predicted to adopt strategies such as pipeline product development and geographic expansion in underdeveloped and developing regions, such as Middle Eastern and West African countries.

As of 2015, federal bodies such as the World Federation Hemophilia have vast information and treatment regulation in about 172 countries, of which 20 were added in 2015, including Nigeria, Togo, Mali, Zambia, Mauritania, and others.

Competitive pricing strategy is a vital factor promoting market players’ growth over the forecast period. For instance, Biogen launched Eloctate in 2014 in the U.S. at a lower price than the existing vastly used drug Advate.

Global Hemophilia market share, by treatment, 2018 (%)

Grand View Research has segmented the global hemophilia market on the basis of type, treatment, therapy, and region.

Global Hemophilia Market by Type 2015 – 2026 (USD Million)

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

Global Hemophilia Market by Treatment 2015 – 2026 (USD Million)

  • On-demand
  • Prophylaxis

Global Hemophilia Market Therapy 2015 – 2026 (USD Million)

  • Replacement Therapy
  • Immune Tolerance Induction Therapy
  • Gene Therapy

Hemophilia Market By Region 2015 – 2026 (USD Million)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

For more information:

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States